Company
Lysoway
Pioneering Lysosomal Ion Channel Modulators for Neurodegeneration
Also known as Lysoway Therapeutics, Lysoway Therapeutics, Inc
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Cambridge, MA, United States
- Legal name
- Lysoway Therapeutics, Inc
Claim, correct or request removal
Record updated 29 September 2026
About
Developing highly brain-penetrant lysosomal ion channel modulators, including TRPML1 and TMEM175 agonists, to restore autophagy-lysosomal function in age-related neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as rare lysosomal disorders.
Funding snapshot
- Total raised
- $22MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series A, $22M2022-10-05
Funding rounds
- Series A
- $22M2022-10-05, Company stated
Loading relationship preview